Home care is the theme for Severe ME Day on August 8th
Why should home care be the theme on Understanding and Remembrance Day for Severe ME on August 8? Helen Brownlie of the 25% ME Group has written an explanation for Phoenix Rising ...
Discuss the article on the Forums.

Small molecule that inhibits androgen receptor could treat prostate cancer

Discussion in 'Other Health News and Research' started by Rosemary, Jun 18, 2010.

  1. Rosemary

    Rosemary Senior Member

    Messages:
    193
    Likes:
    1
    Can anyone please access this article ?

    Androgen receptor

    In vitro and mouse studies identified a small molecule from Geodia lindgreni that inhibits androgen receptor and could treat prostate cancer. Further details on the research, next steps and licensing status are discussed in the article.

    http://www.nature.com/scibx/journal/v3/n24/full/scibx.2010.726.html

    BTW Geodia lindgreni is a marine sponge
     
  2. FernRhizome

    FernRhizome Senior Member

    Messages:
    412
    Likes:
    0
    Rosemary:
    Maybe you should send this to WPI???? Or post it to their site? ~Fern
     
  3. Rosemary

    Rosemary Senior Member

    Messages:
    193
    Likes:
    1
    A good idea ! ... thanks Fern

    Here is some further information

    In vitro and mouse studies identified a small molecule from Geodia lindgreni that inhibits androgen receptor and could treat prostate cancer. Screening and in vitro testing of marine sponge extracts identified a compound that inhibited the N-terminal domain of androgen receptor. In three human prostate cancer cell lines, the compound reduced androgen receptor-dependent proliferation compared with no treatment. In mice with androgen-sensitive and castration-resistant prostate cancer (CRPC) xenografts, the compound reduced tumor growth compared with no treatment. Ongoing work includes optimization of the lead compound.
    MDV3100, a triple-acting oral anti-androgen receptor from Medivation Inc. and Astellas Pharma Inc., is in Phase III testing to treat CRPC.
    Tokai Pharmaceuticals Inc.'s TOK-001, a selective androgen receptor modulator (SARM) and inhibitor of cytochrome P450 17 a-hydroxylase/C17, 20 lyase (CYP17), is in Phase I/II testing to treat CRPC.
    Aragon Pharmaceuticals Inc.'s ARN-509, a small molecule that binds androgen receptor, is in preclinical development to treat CRPC.

    Patented by The University of British Columbia and the BC Cancer Agency; licensing status undisclosed

    Andersen, R.J. et al. Cancer Cell; published online June 13, 2010;
    doi:10.1016/j.ccr.2010.04.027
    Contact: Marianne D. Sadar,
    BC Cancer Agency, Vancouver,
    British Columbia, Canada
    e-mail:
    msadar@bcgsc.ca
     

See more popular forum discussions.

Share This Page